Clinical trial
AVANDAMET Compared to Metformin Evaluation Trial (ACME): A 48-week Randomized, Open-label, Multicenter Study to Compare the Efficacy and Tolerability of AVANDAMET to Metformin Monotherapy in Subjects With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Control on Submaximal Metformin.
NCT00241605 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- AVANDAMET Compared to Metformin Evaluation Trial (ACME): A 48-week Randomized, Open-label, Multicenter Study to Compare the Efficacy and Tolerability of AVANDAMET to Metformin Monotherapy in Subjects With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Control on Submaximal Metformin.
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- June 25, 2003
- Completion date
- December 16, 2005
- Enrollment
- 600
- Sites
- 91
Conditions
As the registry lists them; a condition with its own page is linked.